Comment on "Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials"
Clin Pharmacokinet
.
2018 Nov;57(11):1471-1472.
doi: 10.1007/s40262-018-0697-7.
Authors
Joseph F Standing
1
,
Brian J Anderson
2
,
Stefanie Hennig
3
,
Nick H Holford
4
,
Trevor N Johnston
5
,
Catherijne A J Knibbe
6
,
Dagan O Lonsdale
7
,
Amin Rostami-Hodjegan
8
Affiliations
1
UCL Great Ormond Street Institute for Child Health, Room 661, London, WC1N 1EH, UK. j.standing@ucl.ac.uk.
2
Department of Anaesthesia, University of Auckland, Auckland, New Zealand.
3
School of Pharmacy, The University of Queensland, Brisbane, QLD, Australia.
4
Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand.
5
Certara UK Limited, Simcyp Division, Sheffield, UK.
6
Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, University of Leiden, Leiden, The Netherlands.
7
Department of Clinical Pharmacology, Institute for Infection and Immunity, St George's University of London, London, UK.
8
Centre for Applied Pharmacokinetic Research (CAPKR), University of Manchester, Manchester, UK.
PMID:
30027513
DOI:
10.1007/s40262-018-0697-7
No abstract available
Publication types
Letter
Comment
MeSH terms
Age Factors
Anticonvulsants*
Humans
Lamotrigine*
Triazines
Substances
Anticonvulsants
Triazines
Lamotrigine
Grants and funding
MR/M008665/1/MRC_/Medical Research Council/United Kingdom